Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
PARIS, FRANCE, 21 AUGUST 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis. About navtemadlinNavtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to ruxolitinib for patients […]
Financial Post
First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 57.2 of 100 in the snapshot this page was rendered from.
- Freshness
- 31.2 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 4.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 31.2 of 35. How each signal is calculated.
Filed under Business · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Kartos Therapeutics (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.